Synergistic anticancer effects of curcumin and hinokitiol on gefitinib resistant non-small cell lung cancer cells

Tae Bok Lee, Eun Ju Seo, Ji Yun Lee, Jin Hyun Jun

Research output: Contribution to journalArticle

Abstract

This study evaluated the synergistic effect of curcumin (diferuloylmethane) and hinokitiol (β-thujaplicin), natural product derived phytochemicals, on gefitinib (Iressa) resistant non-small cell lung cancer (NSCLC) cells. Gefitinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), is widely used for lung cancer treatment. However, gefitinib resistance is easily acquired by NSCLC and followed by the development of progressive disease. Curcumin and hinokitiol are well-known bioactive compounds demonstrating anti-inflammation, anti-bacteria and anticancer effects. However, the effects of co-treatment of curcumin and hinokitiol on cancer cells have not been reported. Here, we postulated, for the first time, the possibility of combination therapy with curcumin and hinokitiol for treatment of gefitinib resistant NSCLC via increment of apoptosis and lysosomal enlargement.

Original languageEnglish
Pages (from-to)1667-1671
Number of pages5
JournalNatural Product Communications
Volume13
Issue number12
DOIs
Publication statusPublished - 2018

Keywords

  • Curcumin
  • Gefitinib
  • Hinokitiol
  • Non-small cell lung cancer (NSCLC)
  • Synergistic effect

ASJC Scopus subject areas

  • Pharmacology
  • Plant Science
  • Drug Discovery
  • Complementary and alternative medicine

Fingerprint Dive into the research topics of 'Synergistic anticancer effects of curcumin and hinokitiol on gefitinib resistant non-small cell lung cancer cells'. Together they form a unique fingerprint.

  • Cite this